<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03995524</url>
  </required_header>
  <id_info>
    <org_study_id>F-FR-52120-258</org_study_id>
    <nct_id>NCT03995524</nct_id>
  </id_info>
  <brief_title>Spasticity and Treatment Satisfaction Among Stroke Survivors</brief_title>
  <acronym>REBOT</acronym>
  <official_title>Perceived Spasticity and Treatment Satisfaction Among Stroke Survivors Over the Course of a Complete Treatment Cycle With Botulinum Neurotoxin A (BoNT-A): an Ethnographic Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate, through ethnography, changes in symptom burden and disability and their
      effects/interference on patient functioning, ability to perform activities of daily living
      (ADL) and quality of life (QoL) throughout the duration of one BoNT-A treatment cycle.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2019</start_date>
  <completion_date type="Actual">May 12, 2020</completion_date>
  <primary_completion_date type="Actual">May 12, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of functional limitations in daily life activities</measure>
    <time_frame>monthly for 12 Weeks, or until end of injection cycle whichever occurs first</time_frame>
    <description>Degree of functional limitations in daily life activities (i.e. physical functioning) associated with post-stroke spasticity as assessed by using WHODAS parameters, and identification of their characteristics and changes over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health status in subjects with post-stroke spasticity</measure>
    <time_frame>weekly for 12 Weeks, or until end of injection cycle whichever occurs first</time_frame>
    <description>Health status in subjects with post-stroke spasticity as assessed by using EQ-5D-5L parameters, and identification of their characteristics and changes over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Pain</measure>
    <time_frame>12 weeks</time_frame>
    <description>Severity of Pain as per EQ-5D-5L and a sliding scale. This is a descriptive scale that covers 5 dimensions: mobility, self-care, usual activities,pain/discomfort and anxiety/depression. the scale consist of 5 levels, where level one corresponds to &quot;no problems&quot; and level 5 corresponds to &quot;extreme problem&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Burden of spasticity/treatment</measure>
    <time_frame>Opening interview and ending qualitative interviews, ethnography data which will be provided at discretion of patient/caregiver for 12 weeks or duration of treatment, whichever occurs first, may also support these qualitative analyses</time_frame>
    <description>Themes/domains related to the everyday life experiences of subjects with post-stroke spasticity (e.g. burden disease/treatment) through qualitative analysis of in-depth open-ended interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' satisfaction</measure>
    <time_frame>weekly for 12 weeks or until end of injection cycle whichever occurs first. Opening and closing interview will also explore this</time_frame>
    <description>Subjects Report of Satisfaction with Treatment and their perception/desire of more tailored treatment options</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of feedback between caregivers and stroke survivors</measure>
    <time_frame>opening ( before week 1) and ending ( 2 weeks after end of injection cycle) qualitative interviews</time_frame>
    <description>Agreement between the themes elicited from semi-structured interviews between caregivers and subjects</description>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Spasticity as Sequela of Stroke</condition>
  <eligibility>
    <study_pop>
      <textblock>
        40 Adults subjects (male or female) suffering from post-stroke spasticity (the US, UK,
        France, and Italy), who are treated with BoNT-A in the course of routine clinical practice
        for focal spasticity
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic of post-stroke spasticity more than three months prior to inclusion

          -  At least 6 months on treatment (or two treatment cycles) with BoNT-A injections for
             spasticity according to the decision of the physician

          -  Previous BoNT-A injection cycles did not last for more than 16 weeks

          -  Ambulatory (use of walking aids is acceptable)

        Exclusion Criteria:

          -  Neurological disorder other than stroke

          -  Spasticity-specific treatment changes within 3 months prior to inclusion

          -  Patients who had undergone neurolysis or surgery to the affected limb within 6 months

          -  Concurrent participation in a clinical trial for the treatment of spasticity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ipsen Central Contact</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

